Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 4
1998 2
1999 3
2000 5
2001 5
2002 8
2003 7
2004 11
2005 10
2006 8
2007 5
2008 5
2009 8
2010 5
2011 7
2012 3
2013 8
2014 11
2015 16
2016 24
2017 22
2018 21
2019 14
2020 9
2021 13
2022 10
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

238 results

Results by year

Filters applied: . Clear all
Page 1
Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Shalhout SZ, et al. Among authors: kaufman hl. Nat Rev Clin Oncol. 2023 Mar;20(3):160-177. doi: 10.1038/s41571-022-00719-w. Epub 2023 Jan 11. Nat Rev Clin Oncol. 2023. PMID: 36631681 Review.
Oncolytic viruses: a new class of immunotherapy drugs.
Kaufman HL, Kohlhapp FJ, Zloza A. Kaufman HL, et al. Nat Rev Drug Discov. 2015 Sep;14(9):642-62. doi: 10.1038/nrd4663. Nat Rev Drug Discov. 2015. PMID: 26323545 Free PMC article. Review.
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Galluzzi L, et al. Among authors: kaufman hl. J Immunother Cancer. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337. J Immunother Cancer. 2020. PMID: 32209603 Free PMC article. Review.
Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ, Emerick KS, Kaufman HL, Miller DM. Shalhout SZ, et al. Among authors: kaufman hl. Curr Oncol Rep. 2021 Aug 27;23(11):125. doi: 10.1007/s11912-021-01120-z. Curr Oncol Rep. 2021. PMID: 34448958 Free PMC article. Review.
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Puzanov I, et al. Among authors: kaufman hl. J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z. J Immunother Cancer. 2017. PMID: 29162153 Free PMC article.
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Gross ND, et al. Among authors: kaufman hl. N Engl J Med. 2022 Oct 27;387(17):1557-1568. doi: 10.1056/NEJMoa2209813. Epub 2022 Sep 12. N Engl J Med. 2022. PMID: 36094839 Free PMC article. Clinical Trial.
Clinical landscape of oncolytic virus research in 2020.
Macedo N, Miller DM, Haq R, Kaufman HL. Macedo N, et al. Among authors: kaufman hl. J Immunother Cancer. 2020 Oct;8(2):e001486. doi: 10.1136/jitc-2020-001486. J Immunother Cancer. 2020. PMID: 33046622 Free PMC article. Review.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Andtbacka RH, et al. Among authors: kaufman hl. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014293 Clinical Trial.
Oncolytic Immunotherapy.
Hennessy ML, Bommareddy PK, Boland G, Kaufman HL. Hennessy ML, et al. Among authors: kaufman hl. Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5. Surg Oncol Clin N Am. 2019. PMID: 31079797 Review.
238 results